These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20581794)

  • 41. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinsonism with intramuscular ziprasidone.
    Bilal L; Tsai C; Gasper JJ; Ndlela JC
    Am J Psychiatry; 2005 Dec; 162(12):2392-3. PubMed ID: 16330610
    [No Abstract]   [Full Text] [Related]  

  • 44. Treatment of a tardive dyskinesia patient with temporomandibular disorder: a case report.
    Pekkan G; Kilicoglu A; Algin DI
    J Orofac Pain; 2010; 24(2):212-6. PubMed ID: 20401360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ziprasidone induced symptomatic bradycardia: a case report.
    Menon V; Kattimani S; Ayyanar S
    Aust N Z J Psychiatry; 2011 Sep; 45(9):789. PubMed ID: 21668298
    [No Abstract]   [Full Text] [Related]  

  • 46. Use of clonazepam in an elderly bipolar patient with tardive dyskinesia: a case report.
    Gerding LB; Labbate LA
    Ann Clin Psychiatry; 1999 Jun; 11(2):87-9. PubMed ID: 10440526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
    Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
    Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
    Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
    Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sudden akathisia after a ziprasidone dose reduction.
    Oral ET; Altinbas K; Demirkiran S
    Am J Psychiatry; 2006 Mar; 163(3):546. PubMed ID: 16513883
    [No Abstract]   [Full Text] [Related]  

  • 51. Mania from dose-related ziprasidone augmentation of an SSRI.
    Privitera MR; Maharaj K
    J Clin Psychiatry; 2003 Nov; 64(11):1393-4. PubMed ID: 14658958
    [No Abstract]   [Full Text] [Related]  

  • 52. Ziprasidone induction of hypomania in depression?
    Davis R; Risch SC
    Am J Psychiatry; 2002 Apr; 159(4):673-4. PubMed ID: 11925314
    [No Abstract]   [Full Text] [Related]  

  • 53. Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.
    Yamamoto N; Oda T; Inada T
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):691-4. PubMed ID: 18081635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tardive dystonia due to aripiprazole use in a neuroleptic-naive patient.
    Friedman JH
    J Clin Psychiatry; 2010 May; 71(5):652-3. PubMed ID: 20492857
    [No Abstract]   [Full Text] [Related]  

  • 55. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics.
    Lykouras L; Rizos E; Gournellis R
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1535-6. PubMed ID: 17614184
    [No Abstract]   [Full Text] [Related]  

  • 56. Applying parsimony to "An African patient with ziprasidone intolerance".
    Anders JL
    J Clin Psychiatry; 2005 Nov; 66(11):1491; author reply 1491-2. PubMed ID: 16420091
    [No Abstract]   [Full Text] [Related]  

  • 57. Atypical posttraumatic dystonia treated successfully by botulinum toxin injection.
    Lee SY; Lim JY
    Am J Phys Med Rehabil; 2015 Mar; 94(3):246-9. PubMed ID: 25415396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cocaine use as a risk factor for ziprasidone-induced acute dystonia.
    Duggal HS
    Gen Hosp Psychiatry; 2007; 29(3):278-9. PubMed ID: 17484950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transient agranulocytosis associated with ziprasidone in a 45-year-old man on hemodialysis.
    Iskandar JW; Vance JE; Kablinger A; Kavuru B
    J Clin Psychopharmacol; 2015 Jun; 35(3):347-8. PubMed ID: 25874914
    [No Abstract]   [Full Text] [Related]  

  • 60. A case of severe hyponatremia induced by duloxetine and ziprasidone.
    Li RM; Wang C; Liu ZW; Zhao B
    Chin Med J (Engl); 2012 Oct; 125(20):3750-1. PubMed ID: 23075738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.